Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Botulinum toxin type A for intensified Raynaud's phenomenon in scleroderma
IRCT20200106046023N1Phase 3Completed
- Sponsor
- Urmia University of Medical Sciences
- Start
- Sep 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, single-arm trial of botulinum toxin type A in Raynaud disease and systemic sclerosis (SSc), sponsored by Urmia University of Medical Sciences. Started Sep 2018; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
Raynaud diseasesystemic sclerosis (SSc)
Beyond the preview
Go deeper on IRCT20200106046023N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20200106046023N1.